NCT00488059 arm group 2930ea97bdf5ee68ff22689deb72de17 [clinicaltrials_resource:NCT00488059/arm-group/2930ea97bdf5ee68ff22689deb72de17]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00488059 arm group 2930ea97bdf5ee68ff22689deb72de17 [clinicaltrials_resource:NCT00488059/arm-group/2930ea97bdf5ee68ff22689deb72de17]
Bio2RDF identifier
NCT00488059/arm-group/2930ea97bdf5ee68ff22689deb72de17
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 30ea97bdf5ee68ff22689deb72de17
description [clinicaltrials_vocabulary:description]
Phase 1: ENF 90mg SC BID): In ...... anscriptase inhibitor (NRTIs).
identifier
clinicaltrials_resource:NCT00488059/arm-group/2930ea97bdf5ee68ff22689deb72de17
title
NCT00488059 arm group 2930ea97bdf5ee68ff22689deb72de17
@en
type
label
NCT00488059 arm group 2930ea97 ...... 0ea97bdf5ee68ff22689deb72de17]
@en